These include meloxicam, nimesulide and etodolac. Nabumetone has also been referred to as a preferential inhibitor of COX-2, primarily on the basis of an invitro study suggesting that nabumetone's active metabolite may display preferential COX-2 inhibition; however, this claim has not been confirmed.